Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform December 26, 2024
Positive Interim Ph 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer Announced December 26, 2024
FDA issues CRL for BLA for fixed combination of amivantamab and human hyaluronidase for SC amivantamab in patients with NSCLC with EGFR mutations December 26, 2024
FDA approves Itovebi for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation December 26, 2024
Marker Therapeutics Awarded $9.5 Million Grant from the CPRIT to Support the Investigation of MT-601 in Patients with Pancreatic Cancer December 26, 2024
First patient enrolled in Ph 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA in patients with unresectable or metastatic melanoma December 26, 2024
FAILED TRIAL: Ph 3 Bridging Trial in China in Patients with R/R AML did not demonstrate favorable benefit for uproleselan December 26, 2024
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for 2L Treatment of ES-SCLC December 26, 2024
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics December 26, 2024
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement December 26, 2024
Merck Closes Exclusive Global License Agreement for Anti-PD-1/VEGF Bispecific Antibody LM-299 December 26, 2024
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on PYX-201 program December 26, 2024
